New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

MAHDAL Michal NERADIL Jakub MÚDRY Peter PAUKOVČEKOVÁ Silvia ZAMBO Iva URBAN Jiří MACSEK Peter PAZOUREK Lukáš TOMÁŠ Tomáš VESELSKÁ Renata

Year of publication 2021
Type Article in Periodical
Magazine / Source Cancers
MU Faculty or unit

Faculty of Science

Citation
Web https://www.mdpi.com/2072-6694/13/14/3543
Doi http://dx.doi.org/10.3390/cancers13143543
Keywords giant-cell tumor of bone; targeted treatment; sunitinib; PDGFR beta; denosumab; signaling
Description The purpose of this study was to analyze differential cell signaling in response to denosumab treatment to identify and subsequently inhibit molecular targets in the neoplastic stromal cell population, which poses a risk for tumor recurrence. Using phosphoprotein arrays, a distinct signaling profile was detected in GCTB tissues treated with denosumab, a specific RANKL antibody, which coincided with the RTK profile in derived cell lines. PDGFRß was selected as a promising receptor target, and its inhibition by the small-molecule inhibitor sunitinib resulted in potent inhibition of cell proliferation in vitro. The addition of sunitinib to denosumab resulted in the disappearance of both multinuclear giant cells and neoplastic stromal cells, as reported here. Thus, sunitinib could become an effective addition to denosumab in the treatment of GCTB with activated PDGFRß.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info